Abstract
In adults, acute lymphoblastic leukemia (ALL) is an aggressive malignancy that, while initially highly responsive to chemotherapy, has a high relapse rate and poor survival. The role of allogeneic transplantation in ALL, the use of pediatric strategies in adolescents and young adults, the administration of rituximab for CD20-positive B-lineage ALL, tyrosine kinase inhibitors for Philadelphia chromosome-positive ALL, and nelarabine for T-lineage ALL will be discussed in this article. Promising agents reported in early clinical trials since 2010 are herein highlighted, including antibody-drug and antibody-immunotoxins; blinatumomab (bispecific T-cell engaging antibody); second- and third-generation tyrosine kinase inhibitors; mTOR inhibitors; bortezomib (a proteasome inhibitor); liposomal vincristine (reformulated chemotherapy); and decitabine (a hypomethylating agent). Progress has been made over the last few years in the development of novel therapeutics in ALL and appears to be setting the stage for even...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
